Our pipeline
1859 is focused on discovering next-generation small molecule therapies to disrupt standard-of-care.
We focus on well-validated targets with clear unmet patient needs and design molecules with superior profiles.
We identify novel chemical matter to target biologically relevant targets without approved therapies.
We tackle adaptive resistance to approved therapies and generate molecules that target these mutations.
Pipeline
